(1998) Cancer statistics, 1998,

(2004) Cancer statistics, 2004,

(1997) Small cell lung cancer: state-of-the-art therapy in 1996,

(2001) Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe,

(2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer,

(2004) Recent advances in management of small cell lung cancer,

(2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer,

A meta-analysis of thoracic radiotherapy for small cell lung cancer,

(jclinoncol1992;10) Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis,

(2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited- stage small cell lung cancer: results of the Japan Clinical Oncology Group Study 9104,

(jclinoncol1993;11) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer The National Cancer Institute of Canada Clinical Trials Group,

(1997) Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small cell lung cancer,

(1997) Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer: a randomized study,

WHO handbook for reporting results of cancer treatment,

(2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment,

(jimmunol1994;153) Histamine augments cytokine-stimulated IL-11 production by human lung fibroblasts,

(2005) Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903,

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer,

(2003) Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small cell lung cancer (JCOG9902-DI),

[A phase II study of CPT-11 in patients with primary lung cancer Gan To Kagaku Ryoho 1991;18,

Establishment of a camptothecin analogue -resistant cell line of human non-small cell lung cancer characterization and mechanism of resistance,

(1996) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells,

(2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer,

(jclinoncol1994;12) Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive stage small cell lung cancer,

Endpoints for multimodal clinical trials in Stage III non-small cell lung cancer,

(2006) Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small cell lung cancer,

(jclinoncol1990;8) Determinants of improved outcome in small cell lung cancer an analysis of the 2,

(2000) From bronchoconstriction to airways inflammation and remodeling,

(1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide,

(1999) Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small cell lung carcinoma,